Celldex Therapeutics (CLDX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.96

Estimate

-$1.01

Surprise

+5.0%

Score today

5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Celldex Therapeutics (CLDX) reported a narrower loss than forecast — adjusted EPS of -$0.96 against the -$1.01 estimate (a 5.0% beat on a still-unprofitable quarter).

• Canaccord Genuity Raises Price Target for Celldex Therapeutics — fiscal.ai, 2026-11-06
• Barclays Maintains Bullish Rating on Celldex Therapeutics — fiscal.ai, 2026-11-06
• Celldex Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update — fiscal.ai, 2026-11-05

TrendMatrix currently rates CLDX Sell at 5.7/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +5.0% surprise compares with a -2.6% four-quarter average. Next scheduled report: 2027-02-25.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$29.87

Price target

$54.87

Stop

$27.78

Upside to target

+83.7%

Reward-to-risk

9.0:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.35B

P/E (fwd)

-7.1

52-week range

$22.10–$45.14

Off 52-week high

33.8%

RSI (14)

51

Volume vs avg

0.92×

Score today

5.7/10